Incyte’s US Approval For PD-1 Inhibitor Zynyz In MCC Draws Muted Response
Unlikely To Prove Competitive
The US firm’s Zynyz has won accelerated approval for the treatment of first-line Merkel cell carcinoma, bouncing back from a prior regulatory setback, but its third-to-market status leaves it with the crumbs under the table in this orphan indication.
